Modulators of p-selectin glycoprotein ligand 1

a technology of pselectin and glycoprotein, which is applied in the direction of immunological disorders, drug compositions, peptides, etc., can solve the problems of limiting the therapeutic application of these two antibodies, hampered attempts to use fas and tnfr2 molecules to control unwanted t cells, etc., to prevent immune activation, induce t cell depletion, and/or apoptosis in
US20100080819A1Inactive Publication Date: 2010-04-01ABGENOMICS COOPERATIEF U A
15 Cites 13 Cited by

Patent Information

Authority / Receiving Office
US · United States
Current Assignee / Owner
ABGENOMICS COOPERATIEF U A
Publication Date
2010-04-01
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

Multimeric compounds that bind to P-Selectin Glycoprotein 1 (PSGL-1) on the surface of T cells or natural killer (NK) cells can be used to induce T cell or NK cell depletion and / or to induce T cell or NK cell apoptosis. The multimeric compounds and methods of the invention can be used to control unwanted T cell- or NK cell-mediated immune responses in conditions such as inflammatory diseases, autoimmune diseases, transplant rejection, and allergic diseases.
Need to check novelty before this filing date? Find Prior Art

Description

RELATED APPLICATIONS

[0001] This application is a divisional of U.S. application Ser. No. 10 / 662,906, filed Sep. 15, 2003, which is a continuation-in-part of U.S. application Ser. No. 10 / 051,497, filed Jan. 18, 2002, which claims priority of U.S. Application No. 60 / 310,196, filed Aug. 3, 2001. The prior applications are incorporated herein by reference in their entirety.FIELD OF THE INVENTION

[0002] The invention relates to compositions and methods for controlling immune responses.BACKGROUND OF THE INVENTION

[0003] The control of unwanted immune responses is a critical issue in the treatment of diseases such as inflammatory diseases, autoimmune diseases, transplant rejection, allergic diseases and T cell-derived cancers. The activity of overly aggressive T cells can be controlled by immunosuppression or by the induction of immunological tolerance. Tolerance is defined as a state where the immune system is made unresponsive to an antigen, whereas immunosuppression, which decreases the immu...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More